US 10787490
Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
granted A61KA61K38/00A61P
Quick answer
US patent 10787490 (Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases) held by Protagonist Therapeutics, Inc. expires Mon Sep 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Protagonist Therapeutics, Inc.
- Grant date
- Tue Sep 29 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 18
- CPC classes
- A61K, A61K38/00, A61P, A61P1/04